📰 Williamd Turner News
Williamd Turner News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Williamd Turner. Real-time updates on events, politics, business and more.
January 8, 2024
Vera Therapeutics, Inc. announced the appointments of two industry veterans to help lead the development of the company?s drug programs including its late-stage product candidate, atacicept, to treat...
January 8, 2024
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and...
May 22, 2022
Equities research analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will announce earnings of ($0.95) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($1.02). Sierra […]
May 17, 2022
Sierra Oncology (NASDAQ:SRRA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $61.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside […]
April 13, 2022
Sierra Oncology (NASDAQ:SRRA – Get Rating) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, The Fly reports. They currently have a $55.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 0.60% […]
March 21, 2022
Wall Street brokerages expect that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will post earnings of ($0.91) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sierra Oncology’s earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.85). Sierra Oncology reported earnings per share of […]
March 16, 2022
Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 1,090,000 shares, a growth of 26.4% from the February 13th total of 862,600 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio […]